These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24262766)

  • 1. Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis.
    Kishi T; Meltzer HY; Matsuda Y; Iwata N
    Psychol Med; 2014 Aug; 44(11):2255-69. PubMed ID: 24262766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.
    Kishi T; Meltzer HY; Iwata N
    Int J Neuropsychopharmacol; 2013 Jul; 16(6):1259-66. PubMed ID: 23551924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
    Zheng W; Li XH; Cai DB; Yang XH; Ungvari GS; Ng CH; Ning YP; Xiang YT
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):149-158. PubMed ID: 29174529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties.
    Kaur Gill A; Bansal Y; Bhandari R; Kaur S; Kaur J; Singh R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Jul; 55(7):423-437. PubMed ID: 31347611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.
    Kishi T; Matsunaga S; Iwata N
    Eur Arch Psychiatry Clin Neurosci; 2017 Mar; 267(2):149-161. PubMed ID: 27318835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.
    Celada P; Bortolozzi A; Artigas F
    CNS Drugs; 2013 Sep; 27(9):703-16. PubMed ID: 23757185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 5-HT1A Receptor Partial Agonists of the Azapirone Class as an Add-On Therapy on Psychopathology and Cognition in Schizophrenia: A Systematic Review and Meta-Analysis.
    Yamada R; Wada A; Stickley A; Yokoi Y; Sumiyoshi T
    Int J Neuropsychopharmacol; 2023 Apr; 26(4):249-258. PubMed ID: 36721972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy.
    Hirota T; Schwartz S; Correll CU
    J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):153-73. PubMed ID: 24472251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
    Sahli ZT; Banerjee P; Tarazi FI
    Expert Opin Drug Discov; 2016; 11(5):515-23. PubMed ID: 26971593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of vilazodone on sexual function during the treatment of major depressive disorder.
    Clayton AH; Kennedy SH; Edwards JB; Gallipoli S; Reed CR
    J Sex Med; 2013 Oct; 10(10):2465-76. PubMed ID: 23216998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Iwata N
    J Psychiatr Res; 2013 Sep; 47(9):1143-9. PubMed ID: 23692933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Oya K; Kishi T; Iwata N
    Neuropsychiatr Dis Treat; 2015; 11():2299-307. PubMed ID: 26366084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Meta-Analysis of Memantine for Depression.
    Kishi T; Matsunaga S; Iwata N
    J Alzheimers Dis; 2017; 57(1):113-121. PubMed ID: 28222534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amitriptyline versus placebo for major depressive disorder.
    Leucht C; Huhn M; Leucht S
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD009138. PubMed ID: 23235671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials.
    Kishi T; Sevy S; Chekuri R; Correll CU
    J Clin Psychiatry; 2013 Jul; 74(7):e642-54. PubMed ID: 23945459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
    Lao KS; He Y; Wong IC; Besag FM; Chan EW
    CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.